These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 25773045)

  • 21. [Short-term and long-term outcome of left heart function after cardioverter defibrillator implantation].
    Takeichi K; Kasanuki H; Ohnishi S; Endoh Y; Hosoda S
    J Cardiol; 1996 Nov; 28(5):277-86. PubMed ID: 8953401
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial.
    Zareba W; Daubert JP; Beck CA; Huang DT; Alexis JD; Brown MW; Pyykkonen K; McNitt S; Oakes D; Feng C; Aktas MK; Ayala-Parades F; Baranchuk A; Dubuc M; Haigney M; Mazur A; McPherson CA; Mitchell LB; Natale A; Piccini JP; Raitt M; Rashtian MY; Schuger C; Winters S; Worley SJ; Ziv O; Moss AJ;
    J Am Coll Cardiol; 2018 Aug; 72(6):636-645. PubMed ID: 30071993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics and relevance of clustering ventricular arrhythmias in defibrillator recipients.
    Stuber T; Eigenmann C; Delacrétaz E
    Pacing Clin Electrophysiol; 2005 Jul; 28(7):702-7. PubMed ID: 16008807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients.
    Daubert JP; Zareba W; Hall WJ; Schuger C; Corsello A; Leon AR; Andrews ML; McNitt S; Huang DT; Moss AJ;
    J Am Coll Cardiol; 2006 Jan; 47(1):98-107. PubMed ID: 16386671
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Importance of beta-blocker dose in prevention of ventricular tachyarrhythmias, heart failure hospitalizations, and death in primary prevention implantable cardioverter-defibrillator recipients: a Danish nationwide cohort study.
    Ruwald AC; Gislason GH; Vinther M; Johansen JB; Nielsen JC; Philbert BT; Torp-Pedersen C; Riahi S; Jøns C
    Europace; 2018 Sep; 20(FI2):f217-f224. PubMed ID: 29684191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Right ventricular pacing is an independent predictor for ventricular tachycardia/ventricular fibrillation occurrence and heart failure events in patients with an implantable cardioverter-defibrillator.
    Gardiwal A; Yu H; Oswald H; Luesebrink U; Ludwig A; Pichlmaier AM; Drexler H; Klein G
    Europace; 2008 Mar; 10(3):358-63. PubMed ID: 18308756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Osteopontin and galectin-3 predict the risk of ventricular tachycardia and fibrillation in heart failure patients with implantable defibrillators.
    Francia P; Adduci C; Semprini L; Borro M; Ricotta A; Sensini I; Santini D; Caprinozzi M; Balla C; Simmaco M; Volpe M
    J Cardiovasc Electrophysiol; 2014 Jun; 25(6):609-16. PubMed ID: 24400815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of ventricular tachyarrhythmia in patients with implantable cardioverter-defibrillator and non-ischemic systolic heart failure.
    Jędrzejczyk-Patej E; Mazurek M; Lazar M; Pruszkowska-Skrzep P; Sokal A; Kowalczyk J; Kowalski O; Kalarus Z; Lenarczyk R
    Kardiol Pol; 2023; 81(10):998-1005. PubMed ID: 37936556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia.
    Sy RW; Gollob MH; Klein GJ; Yee R; Skanes AC; Gula LJ; Leong-Sit P; Gow RM; Green MS; Birnie DH; Krahn AD
    Heart Rhythm; 2011 Jun; 8(6):864-71. PubMed ID: 21315846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ventricular tachyarrhythmias in patients receiving an implantable cardioverter-defibrillator for primary versus secondary prophylaxis indications.
    Manuchehry A; Agusala K; Montevecchi M; Kadish A; Passman R
    Pacing Clin Electrophysiol; 2011 May; 34(5):571-6. PubMed ID: 21208242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical course and prognostic relevance of antitachycardia pacing-terminated ventricular tachyarrhythmias in implantable cardioverter-defibrillator patients.
    Kleemann T; Strauss M; Kouraki K; Zahn R
    Europace; 2015 Jul; 17(7):1068-75. PubMed ID: 25687746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time-dependent risk reduction of ventricular tachyarrhythmias in cardiac resynchronization therapy patients: a MADIT-RIT sub-study.
    Stockburger M; Moss AJ; Olshansky B; Klein H; McNitt S; Schuger C; Daubert JP; Goldenberg I; Ruwald AC; Merkely B; Zareba W; Kutyifa V
    Europace; 2015 Jul; 17(7):1085-91. PubMed ID: 25745075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II.
    Vyas AK; Guo H; Moss AJ; Olshansky B; McNitt SA; Hall WJ; Zareba W; Steinberg JS; Fischer A; Ruskin J; Andrews ML;
    J Am Coll Cardiol; 2006 Feb; 47(4):769-73. PubMed ID: 16487843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. QT interval variability and spontaneous ventricular tachycardia or fibrillation in the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients.
    Haigney MC; Zareba W; Gentlesk PJ; Goldstein RE; Illovsky M; McNitt S; Andrews ML; Moss AJ;
    J Am Coll Cardiol; 2004 Oct; 44(7):1481-7. PubMed ID: 15464332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Left ventricle remodeling predicts the recurrence of ventricular tachyarrhythmias in implantable cardioverter defibrillator recipients for secondary prevention.
    Lee WC; Chen HC; Chen YL; Tsai TH; Pan KL; Lin YS; Chen MC
    BMC Cardiovasc Disord; 2016 Nov; 16(1):231. PubMed ID: 27871248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Driving and implantable cardioverter-defibrillator shocks for ventricular arrhythmias: results from the TOVA study.
    Albert CM; Rosenthal L; Calkins H; Steinberg JS; Ruskin JN; Wang P; Muller JE; Mittleman MA;
    J Am Coll Cardiol; 2007 Dec; 50(23):2233-40. PubMed ID: 18061071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator.
    Moss AJ; Greenberg H; Case RB; Zareba W; Hall WJ; Brown MW; Daubert JP; McNitt S; Andrews ML; Elkin AD;
    Circulation; 2004 Dec; 110(25):3760-5. PubMed ID: 15583079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T-peak to T-end interval for prediction of ventricular tachyarrhythmia and mortality in a primary prevention population with systolic cardiomyopathy.
    Rosenthal TM; Stahls PF; Abi Samra FM; Bernard ML; Khatib S; Polin GM; Xue JQ; Morin DP
    Heart Rhythm; 2015 Aug; 12(8):1789-97. PubMed ID: 25998895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial.
    Raitt MH; Connor WE; Morris C; Kron J; Halperin B; Chugh SS; McClelland J; Cook J; MacMurdy K; Swenson R; Connor SL; Gerhard G; Kraemer DF; Oseran D; Marchant C; Calhoun D; Shnider R; McAnulty J
    JAMA; 2005 Jun; 293(23):2884-91. PubMed ID: 15956633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.